Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
4 September 2017
Second stage production capacity enhancement for Ellex iTrackTM catheters to manufacture 50,000 per year in response to strong current demand and a favourable future demand outlook This follows completion of the first stage production capacity enhancement from 10,000 to 20,000 Ellex iTrackTM catheters per year in July 2017 Approximately 10,000 Ellex iTrackTM catheters were sold in the 2017 financial year Planning is also underway to expand total capacity well beyond 50,000 units peryear to keep pace with forecast demand Adelaide, Australia, 1 September 2017 – Ellex Medical Lasers Limited (ASX: ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it will increase the Company’s production capacity of its Ellex iTrackTM product to approximately 50,000 units per annum from a current level of approximately 20,000 units per annum by expanding and upgrading its manufacturing facility in Fremont, California. In July 2017, the production
29 August 2017
Ellex FY17 EBITDA Trading Update – Final Highlights: European Patent granted for Retinal Rejuvenation Laser Patent significantly strengthens Ellex IP position for the proprietary Ellex 2RT®technology Ellex 2RT® targets a significant global unmet need for AMDAdelaide, Australia, 29 August 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it has been granted a European patent titled Retinal Rejuvenation Laser. This patent significantly strengthens the Company’s expanding patent portfolio for the Ellex 2RT® Laser for treatment of Age-Related Macular Degeneration (“AMD”) the leading cause of blindness in the developed world.About Ellex 2RT®Ellex 2RT® is a non-damaging laser treatment that stimulates regeneration of the retinal pigment epithelium (RPE) to preserve vision, and aims to treat the RPE before vision loss occurs — offering a breakthrough treatment option for a range of degenerativ
25 August 2017
Annual Report Year Ended 30 June 2017 Adelaide, Australia, 25 August 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced profit before tax (PBT) for the fiscal year ended 30 June, 2017 as described in the table below. FY17 A$ Million – Reported profit before tax. Lasers & Ultrasound iTrackTM 2RT Corporate Total Revenue 62.4 8.2 0.9 – 71.6 EBITDA/(loss) 7.3 (1.3) (0.4) (4.1) 1.5 Amortisation & interest (2.8) (0.6) – – (3.4) Profit before tax/(loss) 4.5 (1.9) (0.4) (4.1) (1.9) The results for the year were materially impacted by the decision to expand sales and marketing. During the year a total investment of approximately $2.5m was allocated towards sales and marketing of the company’s transformational products in Ellex iTrack & 2RT. On an underlying basis (adjusting currency fluctuations and abnormal expense) 2017 earnings in each of its 3 business segments are as follows: FY17 A$
Annual Report 2016
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.